As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators Pfizer+BioNTech seeking damages based on their respective sales of the Spikevax® and Comirnaty® COVID-19 vaccines. Key suits were filed by third party mRNA and lipid pioneers that, while not having any mRNA-based products on the market themselves, leveraged their patent portfolios claiming a share of the billions of dollars in sales the vaccines have generated. Direct competitors Moderna and Pfizer+BioNTech also clashed in patent litigation beginning in 2022, with cases initiated in the United States and later expanding abroad.
Recent Posts
- Other Barks & Bites for Friday, August 29: CAFC Affirms Prosecution Laches Ruling Against Hyatt; Trump Admin Cancels USPTO CBA; Second Circuit Affirms Lack of Standing in Ripple Trademark Case
- CAFC Dodges Key Issues in Reversing District Court Finding for Google on Prosecution Laches
- CAFC Corrects PTAB’s Inventorship Analysis in First Appeal of AIA Derivation Proceeding
- Brunetti’s Back: Split CAFC Rejects Most of Scandalous Trademark Applicant’s Arguments But Remands for Second Chance at TTAB
- CAFC is Unconvinced by Claim Construction Challenges to ITC’s Robotics Patent Infringement Finding